2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-146147
    Influenza virus-IN-5 2581825-57-0 98%
    Influenza virus-IN-5 (Compound 5f) is an inhibitor of influenza virus hemagglutinin (HA) with an EC50 of 1 nM against influenza A/H3N2 virus.
    Influenza virus-IN-5
  • HY-146157
    SARS-CoV-2-IN-22 2710278-53-6 98%
    SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM.
    SARS-CoV-2-IN-22
  • HY-146165
    Metallo-β-lactamase-IN-8 1610537-25-1 98%
    Metallo-β-lactamase-IN-8 (compound 17) is a potent, reversible and competitive broad-spectrum inhibitor of metallo-β-lactamases (MβLs), with IC50s of 1.3 μM, 5.7 μM, 9.8 μM, and 9.9 μM for L1, ImiS, IMP-1 and VIM-2, respectively. Metallo-β-lactamase-IN-8 exhibits antibacterial activity.
    Metallo-β-lactamase-IN-8
  • HY-146166
    PT4 1280738-47-7 98%
    PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL). PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity.
    PT4
  • HY-146171
    FabH-IN-1 2692652-49-4 98%
    FabH-IN-1 (compound 3f) is an inhibitor of bacterial 3-oxoacyl-[acyl-carrier-protein] synthase 3 (FabH) enzyme which is a broad-spectrum antimicrobial target. FabH-IN-1 is effective against gram-positive and gram-negative. FabH-IN-1 is also a good antioxidant.
    FabH-IN-1
  • HY-146177
    CYP3A4 enzyme-IN-1 2531281-25-9 98%
    CYP3A4 enzyme-IN-1 (compound 59) is a potent antibacterial agent, with a MIC of 1 μg/mL for MRSA. CYP3A4 enzyme-IN-1 exhibits low to moderate inhibitory effects on CYP1A2, CYP2E1, CYP2D6, and CYP3A4 enzymes.
    CYP3A4 enzyme-IN-1
  • HY-146190
    Callophycin A 1345674-93-2 98%
    Callophycin A, a red seaweed derived metabolite, possessing potent activity against Candida albicans with MIC of 62.5~250 mg/L. Callophycin A significantly reduces fungal burden of vaginal candidiasis induced mice, also decreases inflammatory response and immune molecules.
    Callophycin A
  • HY-146191
    Zika virus-IN-1 2527912-80-5 98%
    Zika virus-IN-1 (Compd 2) is a Zika virus inhibitor, with an EC50 of 1.56 μM .
    Zika virus-IN-1
  • HY-146192
    Zika virus-IN-2 2527912-53-2 98%
    Zika virus-IN-2 (Compd 3) is a Zika virus inhibitor, with an EC50 of 7.4 μM .
    Zika virus-IN-2
  • HY-146193
    Zika virus-IN-3 2527915-11-1 98%
    Zika virus-IN-3 (Compd 7) is a Zika virus inhibitor, with an EC50 of 3.4 μM .
    Zika virus-IN-3
  • HY-146196
    Anticandidal agent-1 2548852-85-1 98%
    Anticandidal agent-1 (compound c2) is a potent and broad-spectrum anticandidal agent. Anticandidal agent-1 shows anticandidal activity against C. albicans and C. glabrata, with MIC50 values of 8.65 and 13.51 μg/mL, respectively. Anticandidal agent-1 inhibits biofilm by blocking hyphal elongation and filamentation.
    Anticandidal agent-1
  • HY-146199
    Antibacterial agent 108 900784-30-7 98%
    Antibacterial agent 108 (Compound 1h) is a potent antibacterial agent with a MIC of both 3 μM against MRSA and antibiotic resistance strains.
    Antibacterial agent 108
  • HY-146204
    HIV-1 capsid inhibitor 1 2396382-78-6 98%
    HIV-1 capsid inhibitor 1 is a potent HIV-1 Capsid inhibitor with an EC50 value of 3.13 µM. HIV-1 capsid inhibitor 1 shows antiviral activities.
    HIV-1 capsid inhibitor 1
  • HY-146226
    Viral 2C protein inhibitor 1 1594427-18-5 98%
    Viral 2C protein inhibitor 1 (compound 6aw) is a potent and broad-spectrum enterovirus antiviral agent, inhibiting viral 2C protein. Viral 2C protein inhibitor 1 inhibits multiple strains of EV-D68, EV-A71 and CVB3 with EC50s of 0.1~3.6 µM, and exhibits high selectivity index and relatively low cytotoxicity.
    Viral 2C protein inhibitor 1
  • HY-146248
    TFMU-ADPr 2412923-11-4 98%
    TFMU-ADPr is a selective reporter substrate of SARS-CoV-2 Macro1 (IC50=0.59 μM), with an excitation wavelength (λEx) of 385 nm, and an emission wavelength (λEm) of 502 nm (or 495 nm). TFMU-ADPr can also undergo enzymatic hydrolysis with Poly(ADP-ribose) Glycohydrolase (PARG) sourced from human, Tetrahymena thermophila and ADP-ribosylhydrolase 3 from human to release fluorophores, thereby directly reporting total poly (ADP-ribose) hydrolase activity. TFMU-ADPr binds to the ADPr-binding site of SARS-CoV-2 Macro1, and its TFMU moiety inserts into the narrow hydrophobic groove of this protein. TFMU-ADPr can thus be used to evaluate small-molecule inhibitors targeting PAR hydrolases under in vitro conditions, to investigate the regulatory mechanisms of ADP-ribosyl catabolic enzymes, or to detect PAR hydrolase activity in whole-cell lysate assays. TFMU-ADPr is also applicable to COVID-19-related research.
    TFMU-ADPr
  • HY-146263
    ThrRS-IN-3 3031483-23-2 98%
    ThrRS-IN-3 (compound 36j) is a highly potent threonyl-tRNA synthetase (ThrRS) inhibitor, with an IC50 value of 19 nM and a Kd of 34 nM for Salmonella enterica ThrRS. ThrRS-IN-3 has antibacterial activities.
    ThrRS-IN-3
  • HY-146270
    pUL89 Endonuclease-IN-1 391680-92-5 98%
    pUL89 Endonuclease-IN-1 (Compound 13d) is a potent inhibitor of human cytomegalovirus (HCMV) pUL89 endonuclease with the IC50 value of 0.88 μM and has antiviral activitiy.
    pUL89 Endonuclease-IN-1
  • HY-146271
    pUL89 Endonuclease-IN-2 519021-48-8 98%
    pUL89 Endonuclease-IN-2 (Compound 15k) is a potent inhibitor of human cytomegalovirus (HCMV) pUL89 endonuclease with the IC50 of 3.0 μM. Antiviral activities.
    pUL89 Endonuclease-IN-2
  • HY-146291
    BET-IN-7 303985-05-9 98%
    BET-IN-7 (Compound 1) is a potent inhibitor of BET with a Ki and Kd of 12.27 and 89.3 μM, respectively. BET-IN-7 has the potential for the research of sepsis.
    BET-IN-7
  • HY-146292
    BET-IN-8 2769893-19-6 98%
    BET-IN-8 (Compound 27) is a potent inhibitor of BET with a Ki and Kd of 0.83 and 0.571 μM, respectively. BET-IN-8 ameliorates LPS-induced sepsis in vivo. BET-IN-8 has the potential for the research of sepsis.
    BET-IN-8
Cat. No. Product Name / Synonyms Application Reactivity